Profund Advisors LLC Buys 40,766 Shares of Dyne Therapeutics, Inc. $DYN

Profund Advisors LLC grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 88.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,746 shares of the company’s stock after buying an additional 40,766 shares during the quarter. Profund Advisors LLC owned approximately 0.06% of Dyne Therapeutics worth $1,697,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in Dyne Therapeutics by 9.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock worth $42,570,000 after acquiring an additional 278,466 shares in the last quarter. Aberdeen Group plc raised its stake in Dyne Therapeutics by 15.0% during the 3rd quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock worth $7,043,000 after acquiring an additional 72,770 shares during the period. Vanguard Group Inc. lifted its holdings in Dyne Therapeutics by 27.6% during the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after purchasing an additional 2,109,257 shares in the last quarter. SG Americas Securities LLC purchased a new position in Dyne Therapeutics during the fourth quarter valued at approximately $5,191,000. Finally, Rafferty Asset Management LLC boosted its position in shares of Dyne Therapeutics by 93.4% in the third quarter. Rafferty Asset Management LLC now owns 213,211 shares of the company’s stock worth $2,697,000 after purchasing an additional 102,963 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insider Transactions at Dyne Therapeutics

In related news, insider Douglas Kerr sold 1,564 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $28,715.04. Following the completion of the transaction, the insider directly owned 170,042 shares of the company’s stock, valued at approximately $3,121,971.12. This represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Erick Lucera sold 1,448 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $26,585.28. Following the transaction, the chief financial officer owned 123,925 shares of the company’s stock, valued at $2,275,263. This represents a 1.15% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 1,559,462 shares of company stock valued at $29,814,746. 14.14% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DYN shares. Chardan Capital reissued a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 9th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Evercore set a $33.00 price target on Dyne Therapeutics in a research note on Friday, May 15th. HC Wainwright decreased their price target on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $17.56 on Thursday. The firm has a market cap of $2.90 billion, a price-to-earnings ratio of -5.45 and a beta of 1.08. The firm has a fifty day moving average price of $18.38 and a 200 day moving average price of $18.44. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the company earned ($1.05) earnings per share. As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.